Clinical trial
A Randomized Phase 2 Trial Of Erlotinib With Or Without PF-3512676 For The Treatment Of Patients With Advanced EGFR-Positive Non-Small Cell Lung Cancer After Failure Of At Least One Prior Chemotherapy Regimen
NCT00321815 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase 2 Trial Of Erlotinib With Or Without PF-3512676 For The Treatment Of Patients With Advanced EGFR-Positive Non-Small Cell Lung Cancer After Failure Of At Least One Prior Chemotherapy Regimen
- Lead sponsor
- Pfizer
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2006
- Completion date
- June 30, 2010
- Enrollment
- 43 (actual)
- Sites
- 35
Conditions
As the registry lists them; a condition with its own page is linked.